Published in Biotech Business Week, April 26th, 2004
This written agreement represents the culmination of a number of teleconferences, meetings and protocol revisions occurring over an 8-month period in which the company and FDA refined the study design for this single, pivotal trial. The resulting agreement binds the FDA and the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.